Market news

Key Stats for HIMS Stock52-Week Range: $14 to $65Market Cap: around $6. 9 billionStreet Mean Target: around $31Forward 2-Year Revenue Growth (CAGR): around 30%Forward 2-Year EPS Growth (CAGR): around 18%NTM P/E: around 23xLTM Gross Margin: 69.

Hims & Hers Health has delivered a very strong multi year share price move, and that run now puts fresh attention on whether the current valuation can be supported by its sales base. With recent headlines around new products and regulatory scrutiny, the question is how much of that is already reflected in what investors are paying for each dollar of revenue. Over the past 3 years, Hims & Hers Health has returned about 3.7x for shareholders, which puts significant weight on whether its...

Hims & Hers Health (NYSE:HIMS) introduced an AI native weight loss care platform built around a closed loop clinical system. The new offering uses continuous learning, real time monitoring, and automation to support clinician decisions within the weight loss program. Management positions the platform as a way to scale weight management services while aiming to keep safety controls embedded in workflows. The AI native weight loss care launch matters, but investors also need to weigh other...

Hims & Hers Health (HIMS) has been in the spotlight after a class action lawsuit and related regulatory complaints over data privacy and billing practices, raising fresh questions for investors about risk, governance, and long term business quality. Despite the legal headlines, Hims & Hers Health has seen mixed momentum, with the share price up 5.11% over the last week but down 13.32% across three months. The 1-year total shareholder return has fallen 49.62% after a very large 3-year gain of...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

At first glance, Hims & Hers Health, Inc. (NYSE:HIMS) delivered the kind of result that investors typically reward. Revenue grew 38%, full-year guidance was increased, and the company completed an acquisition that management says positions it as the world’s leading consumer health platform. That made the quarter look like another strong growth report, although the […]

Key TakeawaysGross margin at Hims & Hers has fallen for eight straight quarters, from 79% in September 2024 to 64% in the quarter ended June 2026, even as revenue grew 40% year over year in that same latest quarter. Reported EBITDA margin turned negative in the March 2026 quarter and stayed there in June, at negative 8.

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The insider still retains significant holdings, valued at $8.5 million, despite the sale.

Hims & Hers Health has been hit with an FTC complaint and multiple securities class action lawsuits alleging improper sharing of sensitive health data and misleading billing practices, events that have already drawn regulatory scrutiny and legal pressure by mid‑2026. The allegations cut to the core of Hims & Hers’ telehealth model, putting its privacy assurances and subscription-based business practices under a spotlight that could reshape how it operates. Against this backdrop of FTC action...

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $27.93, indicating a -3.07% shift from the previous trading day.

History says you should avoid HIMS stock right now

Hims & Hers shifts to branded distribution, pressuring margins and FCF despite growth; valuation looks rich. Click for more on HIMS stock.

Hims & Hers Health is still growing rapidly, but whether that growth can translate into better economics could determine how much further the stock can climb.

The weight-loss opportunity now comes with a margin tradeoff

Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $28.17, representing a +1.66% change from its previous close.

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

TDOC's Integrated Care is driving profitability as chronic care gains traction, potentially making it the company's key earnings driver.

HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.

HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.

Hims & Hers Health (NYSE:HIMS) shares fell 3.2% after the FDA warned telehealth companies and compounding pharmacies over unapproved weight-loss drugs, including versions of semaglutide, tirzepatide and retatrutide. The agency said retatrutide and cagrilintide cannot legally be used in...

Hims & Hers Health, Inc. (NYSE:HIMS) has entered Australia, marking its first expansion into the Asia-Pacific market. The move follows its acquisition of Australian digital-health platform Eucalyptus, which includes men’s health brand Pilot and women’s health brand Juniper. Hims is initially rolling out weight-loss and men’s health treatments, with plans to introduce women’s health services […]